Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
IDXX filed a Form 144 reporting a proposed sale of Common Stock through Goldman Sachs & Co. LLC. The filing lists multiple lots of Restricted Stock Units acquired as compensation on 05/11/2022, 05/11/2023, 05/06/2024, 05/06/2025, and 05/07/2026 with indicated share counts.
IDEXX Laboratories, Inc. reported that shareholders approved key governance changes at the 2026 annual meeting. Amendments to the Amended and Restated Certificate of Incorporation will declassify the Board over three years and move to annual elections for all directors beginning with the 2029 annual meeting.
Shareholders also approved giving investors who own at least 25% of the company’s stock continuously for at least one year the right to require the company to call a special shareholder meeting, subject to conditions in the By-Laws. Three Class II directors were elected through 2029, PricewaterhouseCoopers LLP was ratified as auditor, executive pay received advisory approval, and a separate shareholder proposal on special meeting rights was not approved.
IDEXX Laboratories director Sophie V. Vandebroek reported equity compensation grants in the form of restricted stock units and stock options. She received 234 restricted stock units, each representing one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share. Both the units and options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever comes earlier.
IDEXX Laboratories director Sam Samad received new equity awards as part of his board compensation. On May 12, 2026, he was granted 234 deferred stock units, each representing a right to one share of common stock, bringing his deferred stock unit balance to 1,354 units. He also received a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share, with 525 options reported as held after the grant. Both the option and deferred stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs first. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Karen Peacock reported equity compensation awards. She received 234 deferred stock units and a non-qualified stock option covering 525 shares of common stock, both recorded as grants, not open-market purchases.
The stock option has an exercise price of $533.92 per share and expires in May 2036. Both the option and the deferred stock units vest in a single installment on the earlier of one year from grant or the 2027 annual meeting of shareholders. The deferred stock units are payable in common stock after her resignation from the board.
IDEXX Laboratories director Lawrence D. Kingsley reported multiple equity awards. On May 12, 2026, he received grants of restricted stock units covering 75 and 234 shares of common stock. Each unit represents a contingent right to receive one share.
He was also granted non-qualified stock options for 168 and 525 shares of common stock at an exercise price of $533.92 per share. According to the footnotes, these RSUs and options vest in a single installment on the one-year anniversary of the grant date or on the date of IDEXX’s 2027 annual meeting of shareholders, whichever occurs earlier. The options expire on May 11, 2036.
IDEXX Laboratories Inc. reported that director Daniel M. Junius received new equity awards. On May 12, 2026, he was granted 234 restricted stock units, each representing a contingent right to one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share.
According to the terms, both the options and the restricted stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. Following these grants, the filing shows 234 restricted stock units and 525 options from this award held directly.
IDEXX Laboratories director Joseph L. Hooley reported new equity awards. On May 12, 2026, he received 234 deferred stock units and 525 non-qualified stock options. The options have an exercise price of $533.92 per share and expire on May 11, 2036.
Both the deferred stock units and the options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are generally payable in common stock after Mr. Hooley resigns from the board.
IDEXX Laboratories director Stuart Essig reported receiving equity compensation awards. He was granted 234 restricted stock units and a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share. Both awards vest in a single installment after about one year or on the 2027 annual shareholder meeting date, whichever comes first.
IDEXX Laboratories director Bruce L. Claflin received new equity awards as part of his board compensation. He was granted 234 deferred stock units, each representing a contingent right to receive one share of common stock, bringing his deferred stock unit balance to 1,354 units.
He was also granted 525 non-qualified stock options to buy common stock at an exercise price of $533.9200 per share, all held directly. Both the options and deferred stock units vest in one installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are, by default, payable in common stock after his resignation from the board.